Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F R Appelbaum

Showing results (291-300 of 490) with videos related to

Pageof 49
Sort By:
Haematology and Blood Transfusion|January 1, 1990
Supportive care of the marrow transplant recipient: the Seattle ExperienceK M Sullivan, J Meyers, F B Petersen, et al.
Blood|September 1, 1995
A retrospective analysis of the long-term effect of splenectomy on late infections, graft-versus-host disease, relapse, and survival after allogeneic marrow transplantation for chronic myelogenous leukemiaP Kalhs, I Schwarzinger, G Anderson, et al.
Blood|October 1, 1992
Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexateR A Nash, M S Pepe, R Storb, et al.
Blood|May 15, 1994
Unrelated donor or autologous marrow transplantation for treatment of acute leukemiaA Busca, C Anasetti, G Anderson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1989
Analysis of prognostic factors for the outcome of marrow transplantation or further chemotherapy for patients with acute nonlymphocytic leukemia in first remissionM S Tallman, K J Kopecky, D Amos, et al.
The New England Journal of Medicine|March 30, 1989
Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasmsK M Sullivan, R Storb, C D Buckner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1996
Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factorsJ E Anderson, F R Appelbaum, G Schoch, et al.
Bone Marrow Transplantation|January 1, 1991
Long-term follow-up of patients who received recombinant human granulocyte-macrophage colony stimulating factor after autologous bone marrow transplantation for lymphoid malignancyJ Nemunaitis, J W Singer, C D Buckner, et al.
Blood|September 6, 2001
The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantationJ P Radich, T Gooley, E Bryant, et al.
Bone Marrow Transplantation|November 1, 1988
Simultaneous infusion of high-dose cytosine arabinoside with cyclophosphamide followed by total body irradiation and marrow infusion for the treatment of patients with advanced hematological malignancyF B Petersen, F R Appelbaum, C D Buckner, et al.
Pageof 49

Showing results (291-300 of 490) with videos related to

Sort By:
Pageof 49
Haematology and Blood Transfusion|January 1, 1990
Supportive care of the marrow transplant recipient: the Seattle ExperienceK M Sullivan, J Meyers, F B Petersen, et al.
Blood|September 1, 1995
A retrospective analysis of the long-term effect of splenectomy on late infections, graft-versus-host disease, relapse, and survival after allogeneic marrow transplantation for chronic myelogenous leukemiaP Kalhs, I Schwarzinger, G Anderson, et al.
Blood|October 1, 1992
Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexateR A Nash, M S Pepe, R Storb, et al.
Blood|May 15, 1994
Unrelated donor or autologous marrow transplantation for treatment of acute leukemiaA Busca, C Anasetti, G Anderson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1989
Analysis of prognostic factors for the outcome of marrow transplantation or further chemotherapy for patients with acute nonlymphocytic leukemia in first remissionM S Tallman, K J Kopecky, D Amos, et al.
The New England Journal of Medicine|March 30, 1989
Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasmsK M Sullivan, R Storb, C D Buckner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1996
Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factorsJ E Anderson, F R Appelbaum, G Schoch, et al.
Bone Marrow Transplantation|January 1, 1991
Long-term follow-up of patients who received recombinant human granulocyte-macrophage colony stimulating factor after autologous bone marrow transplantation for lymphoid malignancyJ Nemunaitis, J W Singer, C D Buckner, et al.
Blood|September 6, 2001
The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantationJ P Radich, T Gooley, E Bryant, et al.
Bone Marrow Transplantation|November 1, 1988
Simultaneous infusion of high-dose cytosine arabinoside with cyclophosphamide followed by total body irradiation and marrow infusion for the treatment of patients with advanced hematological malignancyF B Petersen, F R Appelbaum, C D Buckner, et al.
Pageof 49